RxDoctor Payments Data

Barry Schanzer, MD

Ophthalmology · Edison, NJNPI 1053456509

Payments from drug & device makers

$2,336in general payments, 2019–2025

Across 177 payments — averaging $13.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$485
  • AbbVie$322
  • Alcon$276
  • Biotissue Holdings Inc.$172
  • Bausch & Lomb Americas Inc.$154
  • Harrow Eye, LLC$143
  • plus $784 from 18 others

What the payments were for

  • Food & beverage$2,29998%
  • Education$181%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,336 in reported general payments places this provider in the 60th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$731,087
Medicare patients
1,686
Services billed
7,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost330$168,048
XiidraLifitegrast66$74,770
RestasisCyclosporine90$74,654
Cyclosporine50$31,901
CombiganBrimonidine Tartrate/Timolol47$21,942
MieboPerfluorohexyloctane/Pf18$21,514
TyrvayaVarenicline Tartrate12$11,961
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$10,648
RocklatanNetarsudil Mesylat/Latanoprost27$10,058
Alphagan PBrimonidine Tartrate22$9,841
Travoprost41$9,581
SimbrinzaBrinzolamide/Brimonidine Tart46$9,338
Brimonidine Tartrate52$7,950
RhopressaNetarsudil Mesylate18$6,285
Brinzolamide29$6,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$322$274,484489 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$154$96,28484 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$39$16,34345 claims
Oyster Point Pharma, Inc.Tyrvaya$80$11,96112 claims
AlconSimbrinza$276$9,33846 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$60$2,12911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →